/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology.

/--AbbVie（纽约证券交易所：ABBV）和Neomorph，Inc.今天宣布了一项合作和许可协议，以开发用于肿瘤学和免疫学多个靶标的新型分子胶降解剂。

Molecular glue degraders are a novel class of small molecules that are designed to selectively target and trigger degradation of proteins that drive cancer growth or immune system dysregulation, offering a more precise approach to treatment. Molecular glue degraders have the potential to target proteins that have historically been defined as 'undruggable'..

分子胶降解剂是一类新型小分子，旨在选择性靶向并触发驱动癌症生长或免疫系统失调的蛋白质降解，从而提供更精确的治疗方法。分子胶降解剂有可能靶向历史上被定义为“不可成药”的蛋白质。

'Protein degraders represent a groundbreaking advancement in the field of drug discovery and at AbbVie we are committed to advancing this technology forward,' said

他说：“蛋白质降解剂代表了药物发现领域的突破性进展，在艾伯维，我们致力于推进这项技术的发展。”

Steven Elmore

史蒂芬 埃尔莫尔

, vice president, small molecule therapeutics and platform technologies at AbbVie. 'We are excited to collaborate with Neomorph to develop novel molecular glue degraders which could pave the way for new, effective therapies in the treatment of immune disorders and cancer.'

，AbbVie小分子治疗和平台技术副总裁我们很高兴与Neomorph合作开发新型分子胶降解剂，这可能为治疗免疫疾病和癌症的新的有效疗法铺平道路。”

'At Neomorph, we have spent years building a unique molecular glue platform with broad coverage of the proteome,' said

“在Neomorph，我们花了数年时间构建了一个独特的分子胶平台，该平台覆盖了广泛的蛋白质组，”他说

Phil Chamberlain

菲尔·张伯伦

, DPhil, Co-Founder, President, and Chief Executive Officer of Neomorph. 'We are thrilled to partner with AbbVie, a global leader in delivering transformative medicines in oncology and immunology, as we aim to tackle some of the most challenging and valuable targets known.'

，DPhil，Neomorph的联合创始人、总裁兼首席执行官。”我们很高兴能与全球领先的肿瘤和免疫学转化药物供应商AbbVie合作，因为我们的目标是解决一些已知的最具挑战性和最有价值的目标。”

Under terms of the agreement, Neomorph will receive an upfront payment from AbbVie, and is eligible to receive up to

根据协议条款，Neomorph将从AbbVie获得预付款，并有资格获得多达

$1.64 billion

16.4亿美元

in aggregate option fees and milestones, as well as tiered royalties on net sales.

总的期权费和里程碑，以及净销售额的分层版税。

About AbbVie

关于AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie's Allergan Aesthetics portfolio.

AbbVie的使命是发现并提供创新药物和解决方案，以解决当今严重的健康问题，并应对未来的医疗挑战。AbbVie致力于在几个关键治疗领域（免疫学、肿瘤学、神经科学和眼部护理）以及AbbVie Allergan美学组合中的产品和服务中对人们的生活产生显着影响。

Neomorph is a biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against 'undruggable' targets. Neomorph was founded in 2020 and is venture-backed by Deerfield Management Company.

Neomorph是一家生物技术公司，通过发现和开发针对“不可药用”目标的创新新药，解决人类健康的关键问题。Neomorph成立于2020年，由Deerfield管理公司支持。

Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who have a track record of groundbreaking discoveries in the field. The team at Neomorph is committed to leadership in advancing the science and technology of molecular glue drug discovery, while prosecuting a pipeline of projects through clinical development..

Neomorph的团队由蛋白质降解和分子胶领域的业界领先专家组成，他们在该领域有开创性的发现。Neomorph的团队致力于领导分子胶药物发现的科学和技术，同时通过临床开发起诉一系列项目。。